NO312334B1 - V¶skefylt mykgelatinkapsel og fremstilling derav - Google Patents
V¶skefylt mykgelatinkapsel og fremstilling derav Download PDFInfo
- Publication number
- NO312334B1 NO312334B1 NO19943563A NO943563A NO312334B1 NO 312334 B1 NO312334 B1 NO 312334B1 NO 19943563 A NO19943563 A NO 19943563A NO 943563 A NO943563 A NO 943563A NO 312334 B1 NO312334 B1 NO 312334B1
- Authority
- NO
- Norway
- Prior art keywords
- capsule
- soft gelatin
- propylene glycol
- capsule shell
- gelatin
- Prior art date
Links
- 239000007903 gelatin capsule Substances 0.000 title claims abstract description 52
- 239000007788 liquid Substances 0.000 title claims abstract description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 153
- 239000002775 capsule Substances 0.000 claims abstract description 151
- 108010010803 Gelatin Proteins 0.000 claims abstract description 55
- 239000008273 gelatin Substances 0.000 claims abstract description 55
- 229920000159 gelatin Polymers 0.000 claims abstract description 55
- 235000019322 gelatine Nutrition 0.000 claims abstract description 55
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 55
- 238000011049 filling Methods 0.000 claims abstract description 44
- 239000002904 solvent Substances 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 18
- 239000004014 plasticizer Substances 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 72
- 239000012141 concentrate Substances 0.000 claims description 40
- 239000000463 material Substances 0.000 claims description 40
- 239000004530 micro-emulsion Substances 0.000 claims description 40
- 238000001816 cooling Methods 0.000 claims description 21
- 239000013543 active substance Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000002826 coolant Substances 0.000 claims description 13
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 9
- 229960001265 ciclosporin Drugs 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 108010036949 Cyclosporine Proteins 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 229930182912 cyclosporin Natural products 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- -1 ethyl rapamycin Chemical compound 0.000 claims description 7
- 229960002930 sirolimus Drugs 0.000 claims description 5
- 239000006184 cosolvent Substances 0.000 claims description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 4
- 229930105110 Cyclosporin A Natural products 0.000 claims description 3
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 claims description 2
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 108010019249 cyclosporin G Proteins 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 abstract description 64
- 239000012752 auxiliary agent Substances 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 description 23
- 239000000203 mixture Substances 0.000 description 23
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000600 sorbitol Substances 0.000 description 8
- 239000011521 glass Substances 0.000 description 7
- 230000005012 migration Effects 0.000 description 6
- 238000013508 migration Methods 0.000 description 6
- 108010036941 Cyclosporins Proteins 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 4
- 150000004671 saturated fatty acids Chemical class 0.000 description 4
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 2
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- CKOZVEHVVHCMGD-UHFFFAOYSA-N 5-[(4-fluorophenyl)methyl]-n,n-dimethyltetrazole-1-carboxamide Chemical compound CN(C)C(=O)N1N=NN=C1CC1=CC=C(F)C=C1 CKOZVEHVVHCMGD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241001647839 Streptomyces tsukubensis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 1
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Cosmetics (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20020629A NO324355B1 (no) | 1993-09-28 | 2002-02-08 | Vaeskefylt mykgelatinkapsel |
| NO20020628A NO324852B1 (no) | 1993-09-28 | 2002-02-08 | Mykgelatinkapsler og deres fremstilling |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4332931 | 1993-09-28 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO943563D0 NO943563D0 (no) | 1994-09-26 |
| NO943563L NO943563L (no) | 1995-03-29 |
| NO312334B1 true NO312334B1 (no) | 2002-04-29 |
Family
ID=6498793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19943563A NO312334B1 (no) | 1993-09-28 | 1994-09-26 | V¶skefylt mykgelatinkapsel og fremstilling derav |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US5985321A (cs) |
| EP (3) | EP1033128B2 (cs) |
| JP (1) | JP3071642B2 (cs) |
| KR (1) | KR100200174B1 (cs) |
| CN (2) | CN100473377C (cs) |
| AT (2) | ATE398448T1 (cs) |
| AU (1) | AU690571B2 (cs) |
| CA (3) | CA2302963C (cs) |
| CZ (1) | CZ290314B6 (cs) |
| DE (2) | DE69435104D1 (cs) |
| DK (2) | DK0649651T3 (cs) |
| ES (2) | ES2152281T3 (cs) |
| FI (1) | FI120718B (cs) |
| FR (1) | FR2710532B1 (cs) |
| GB (1) | GB2282586B (cs) |
| GR (1) | GR3035179T3 (cs) |
| HU (2) | HU221681B1 (cs) |
| IL (1) | IL111067A (cs) |
| IT (1) | IT1274931B (cs) |
| NO (1) | NO312334B1 (cs) |
| NZ (1) | NZ264536A (cs) |
| PE (1) | PE31295A1 (cs) |
| PL (1) | PL178884B1 (cs) |
| PT (2) | PT1033128E (cs) |
| RU (1) | RU2140783C1 (cs) |
| SG (1) | SG46531A1 (cs) |
| SI (2) | SI0649651T1 (cs) |
| SK (2) | SK284268B6 (cs) |
| TW (1) | TW438609B (cs) |
| ZA (1) | ZA947567B (cs) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59301262D1 (de) * | 1992-01-17 | 1996-02-08 | Alfatec Pharma Gmbh | Verfahren zur herstellung von weichgelatinekapseln nach einem tropfverfahren |
| US6204243B1 (en) | 1993-09-01 | 2001-03-20 | Novatis Ag | Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis |
| EP1033128B2 (en) * | 1993-09-28 | 2011-11-23 | R.P. Scherer GmbH | Soft gelatin capsule manufacture |
| GB2308545B (en) * | 1994-10-26 | 1999-06-02 | Novartis Ag | Pharmaceutical microemulsion preconcentrates |
| US7205279B2 (en) * | 1995-10-25 | 2007-04-17 | Novartis Ag | Pharmaceutical compositions |
| PE52896A1 (es) * | 1994-10-26 | 1996-12-12 | Novartis Ag | Composicion farmaceutica |
| US5603951A (en) * | 1994-11-09 | 1997-02-18 | Hanmi Pharm. Ind. Co., Ltd. | Cyclosporin-containing soft capsule compositions |
| NZ280689A (en) * | 1995-12-15 | 1997-08-22 | Bernard Charles Sherma Sherman | Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| JPH1071186A (ja) * | 1996-08-29 | 1998-03-17 | Shionogi & Co Ltd | カプセルのバンドシール形成方法 |
| KR20040004416A (ko) * | 1997-01-30 | 2004-01-13 | 노파르티스 아게 | 오일을 함유하지 않은 사이클로스포린 ａ 함유 제약 조성물 |
| EP0982035B1 (en) * | 1998-08-18 | 2004-03-31 | Panacea Biotec Limited | Cyclosporin composition comprising an hydrophilic carrier |
| RU2219911C2 (ru) * | 1998-11-17 | 2003-12-27 | Ф.Хоффманн-Ля Рош Аг | Способ изготовления заполненных жидкостью капсул |
| WO2000040219A1 (en) | 1998-12-30 | 2000-07-13 | Dexcel Ltd. | Dispersible concentrate for the delivery of cyclosporin |
| US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
| EA004872B1 (ru) * | 1999-08-03 | 2004-08-26 | ЛИЛЛИ АЙКОС эЛ-эЛ-Си | β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ |
| JP4601100B2 (ja) * | 1999-11-08 | 2010-12-22 | 三生医薬株式会社 | マスティックの油液を内包した軟カプセル |
| US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
| GB0006430D0 (en) * | 2000-03-17 | 2000-05-03 | Stanelco Fibre Optics Ltd | Capsules |
| ATE370744T1 (de) * | 2000-09-18 | 2007-09-15 | Rpg Life Sciences Ltd | Selbstemulgierende formulierung mit erhöhter bioverfügbarkeit und immunsupprimierender wirkung |
| OA12522A (en) * | 2000-10-12 | 2006-05-30 | Boehringer Ingelheim Pharma | Novel tiotropium-containing inhalation powder. |
| DE60132103T2 (de) * | 2000-10-31 | 2008-04-17 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Perorale, selbst-emulgierende darreichungsformen von pyranon-proteaseinhibitoren |
| RU2207870C2 (ru) * | 2000-11-10 | 2003-07-10 | Панацея Биотек Лимитед | Фармацевтическая композиция, включающая циклоспорин в качестве активного ингредиента |
| JP4214350B2 (ja) * | 2001-01-15 | 2009-01-28 | 日本電気株式会社 | 携帯電話のｓｉｍカード取り付け構造 |
| US20030138483A1 (en) * | 2001-05-25 | 2003-07-24 | Sergio Petriconi | Soft elastic capsules and compositions thereof |
| US20030070679A1 (en) * | 2001-06-01 | 2003-04-17 | Boehringer Ingelheim Pharma Kg | Capsules containing inhalable tiotropium |
| US20040013732A1 (en) * | 2001-09-25 | 2004-01-22 | Michael Farber | Starch-based delivery system for creatine |
| ES2330625T3 (es) * | 2001-10-19 | 2009-12-14 | Isotechnika Inc. | Preconcentrados de microemulsion de analogos de ciclosporina novedosos. |
| US6752953B2 (en) * | 2001-12-03 | 2004-06-22 | Yung Shin Pharmaceutical Co., Ltd. | Method for manufacturing hard non-gelatin pharmaceutical capsules |
| KR20030062894A (ko) * | 2002-01-21 | 2003-07-28 | 주식회사 보창 | 소프트젤라틴캡슐제조기의 성형드럼 냉각장치 |
| US7067150B2 (en) | 2002-04-16 | 2006-06-27 | Scepter Holdings, Inc. | Delivery systems for functional ingredients |
| HRP20050077B1 (hr) * | 2002-07-29 | 2013-11-22 | Alza Corporation | Postupci i oblici doziranja za kontrolirano oslobađanje paliperidona |
| US7763280B2 (en) * | 2002-11-28 | 2010-07-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing powder formulation for inhalation |
| KR100525234B1 (ko) * | 2003-02-19 | 2005-10-28 | 한국유나이티드제약 주식회사 | 사이클로스포린 함유 연질캅셀제 및 그 제조방법 |
| US7134978B2 (en) * | 2003-07-28 | 2006-11-14 | Sagittarius Life Science Corporation | Seamless BB paintball |
| USD520635S1 (en) | 2003-09-16 | 2006-05-09 | Novartis Ag | Combine capsule and tablets |
| USD530814S1 (en) | 2003-09-16 | 2006-10-24 | Novartis Ag | Combined capsule and tablets |
| US7247010B2 (en) * | 2003-10-01 | 2007-07-24 | Technophar Equipment & Service Limited | Servo control for capsule making machine |
| FR2861992B1 (fr) * | 2003-11-10 | 2007-07-20 | Sanofi Synthelabo | Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide. |
| EP1706700A2 (en) * | 2003-11-12 | 2006-10-04 | National Paintball Supply, Inc. | Projectile, projectile core, and method of making |
| US20050175686A1 (en) * | 2004-02-11 | 2005-08-11 | Ramachandran Radhakrishnan | Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule |
| JP2005255677A (ja) * | 2004-02-12 | 2005-09-22 | Nof Corp | シクロスポリン製剤 |
| US20080160086A1 (en) * | 2004-02-19 | 2008-07-03 | Scepter Holdings, Inc. | Delivery Systems For Calcium |
| US20060153824A1 (en) * | 2005-01-13 | 2006-07-13 | Everett Laboratories, Inc. | Methods and kits for co-administration of nutritional supplements |
| EP1885342B8 (en) * | 2005-03-21 | 2016-06-22 | Teva Czech Industries s.r.o. | Crystallization inhibitor and its use in gelatin capsules |
| US20060275361A1 (en) * | 2005-06-03 | 2006-12-07 | Cadbury Adams Usa Llc. | Rapidly dissolving gelatin compositions and products made therefrom |
| EA015922B1 (ru) | 2005-11-14 | 2011-12-30 | Ариад Фармасьютикалз, Инк. | ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ |
| CN1919194A (zh) * | 2006-08-17 | 2007-02-28 | 刘瑜玲 | 西罗莫司的液体组合物 |
| WO2008106787A1 (en) * | 2007-03-06 | 2008-09-12 | Bioriginal Food & Science Corporation | Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same |
| US20090110724A1 (en) * | 2007-10-31 | 2009-04-30 | Everett Laboratories, Inc. | Compositions and methods for treatment of pain |
| RS53292B (sr) | 2008-09-16 | 2014-08-29 | Boehringer Ingelheim International Gmbh | Kristalni oblici 2-tiazolil-4-hinolinil-oksi derivata, snažni hcv inhibitor |
| CN102292078A (zh) | 2008-11-11 | 2011-12-21 | 得克萨斯大学体系董事会 | 哺乳动物雷帕霉素靶蛋白的抑制 |
| SG177569A1 (en) | 2009-07-07 | 2012-03-29 | Boehringer Ingelheim Int | Pharmaceutical composition for a hepatitis c viral protease inhibitor |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
| GB201006012D0 (en) * | 2010-04-09 | 2010-05-26 | Ayanda As | Composition |
| WO2012010980A2 (en) * | 2010-07-19 | 2012-01-26 | Procaps Sa | Improved apparatus and process for making soft gel capsules |
| AP2013006733A0 (en) | 2010-09-30 | 2013-02-28 | Boehringer Ingelheim Int | Solid state forms of a potent HCV inhibitor |
| US20120107395A1 (en) * | 2010-11-01 | 2012-05-03 | Viva Pharmaceutical Inc. | Probiotic Soft Gel Compositions |
| US8621764B2 (en) | 2011-03-16 | 2014-01-07 | John PUCKETT | Gelatin capsule formulation and drying system |
| WO2012138669A1 (en) | 2011-04-04 | 2012-10-11 | Gilead Sciences, Inc. | Solid state forms of hiv inhibitor |
| CN103732255B (zh) * | 2011-09-02 | 2016-04-06 | 富士胶片株式会社 | 软胶囊制剂、软胶囊制剂用组合物及软胶囊制剂的制造方法 |
| US20130261134A1 (en) | 2012-03-30 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Mesylate salt forms of a potent hcv inhibitor |
| US20140094485A1 (en) | 2012-10-03 | 2014-04-03 | Gilead Sciences, Inc. | Solid state forms of hiv inhibitor |
| EP2968281B1 (en) | 2013-03-13 | 2020-08-05 | The Board of Regents of The University of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
| CN103315975B (zh) * | 2013-06-05 | 2015-09-02 | 天津科技大学 | 一种明胶-CaCO3矿物质胶囊壳及其制备方法 |
| LT3024463T (lt) * | 2013-07-25 | 2020-07-10 | Neuren Pharmaceuticals Limited | Neuroapsauginiai bicikliniai junginiai ir jų panaudojimo būdai autizmo spektro sutrikimų ir neuroliginių vystymosi sutrikimų gydymui |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| ES2900426T3 (es) | 2013-12-31 | 2022-03-16 | Rapamycin Holdings Llc | Preparaciones orales y uso de nanopartículas de rapamicina |
| US20180243224A1 (en) * | 2015-08-19 | 2018-08-30 | Vivus, Inc. | Pharmaceutical formulations |
| CN112240659A (zh) * | 2020-10-17 | 2021-01-19 | 温州桑盾信息科技有限公司 | 一种胶囊机安全防护用自动降温机构 |
| KR102874663B1 (ko) * | 2021-12-22 | 2025-10-23 | 알고케어 주식회사 | 구 형상의 제형을 제공하는 디스펜서 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4198391A (en) * | 1973-07-20 | 1980-04-15 | R. P. Scherer Ltd. | Pharmaceutical compositions |
| US3870547A (en) | 1974-01-24 | 1975-03-11 | Owens Corning Fiberglass Corp | Starch coated fibers for embedding in resin matrix forming materials and composites so formed |
| AT366576B (de) * | 1974-02-22 | 1982-04-26 | Wellcome Found | Verfahren zur herstellung von pharmazeutischen praeparaten |
| GB1508770A (en) | 1974-04-01 | 1978-04-26 | Scherer Ltd R | Pharmaceutical compositions |
| US4067960A (en) * | 1975-06-20 | 1978-01-10 | R. P. Scherer Limited | Pharmaceutical compositions containing cardiac glycoside |
| SE445174B (sv) * | 1978-03-07 | 1986-06-09 | Sandoz Ag | Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans |
| JPS5933018B2 (ja) * | 1980-03-17 | 1984-08-13 | 森下仁丹株式会社 | 高融点物質のマイクロカプセル製造方法とその製造装置 |
| DE3237814A1 (de) * | 1982-10-12 | 1984-04-12 | Warner-Lambert Co., 07950 Morris Plains, N.J. | Wasserfreie emulsionen und verwendung derselben |
| DE3307353C2 (de) * | 1983-03-02 | 1985-01-31 | R.P. Scherer GmbH, 6930 Eberbach | Polyethylenglykolhaltige Weichgelatinekapsel und Verfahren zu ihrer Herstellung |
| GB8305693D0 (en) * | 1983-03-02 | 1983-04-07 | Scherer Ltd R P | Pharmaceutical compositions |
| DE3406497A1 (de) | 1984-02-23 | 1985-09-05 | Mueller Bernhard Willi Werner | Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung |
| US4609403A (en) * | 1984-03-12 | 1986-09-02 | Warner-Lambert Company | Foam soft gelatin capsules and their method of manufacture |
| US4713246A (en) | 1984-03-19 | 1987-12-15 | Bristol-Myers Company | Etoposide oral dosage form |
| DE3579384D1 (de) * | 1984-07-24 | 1990-10-04 | Scherer Gmbh R P | Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung. |
| DE3445237C1 (de) * | 1984-12-12 | 1986-06-05 | R.P. Scherer GmbH, 6930 Eberbach | Weichgelatinekapseln und Verfahren zu ihrer Herstellung |
| DE3529694A1 (de) | 1985-08-20 | 1987-02-26 | Scherer Gmbh R P | Gelatinekapseln und verfahren zu ihrer herstellung |
| JPS62207460A (ja) | 1986-03-07 | 1987-09-11 | 株式会社三協 | ゼラチンカプセルの製造装置におけるゼラチンシ−ト成型装置 |
| EP0240581B1 (de) | 1986-04-05 | 1991-01-02 | R.P. Scherer GmbH | Gelatinekapseln mit gesteuerter Wirkstofffreisetzung und Verfahren zur Herstellung derselben |
| DE3629386A1 (de) * | 1986-08-29 | 1988-03-03 | Scherer Gmbh R P | Gelatinekapseln und verfahren zu ihrer herstellung |
| US4927638A (en) * | 1986-10-08 | 1990-05-22 | Bristol-Myers Company | Etoposide solutions |
| US5154930A (en) * | 1987-03-05 | 1992-10-13 | The Liposome Company, Inc. | Pharmacological agent-lipid solution preparation |
| JPS63309264A (ja) | 1987-06-10 | 1988-12-16 | Kamata Seisakusho:Kk | ソフトカプセル製造機 |
| US4817367A (en) * | 1987-08-10 | 1989-04-04 | Sankyo Co., Ltd. | Apparatus for manufacturing gelatin capsule and method therefor |
| GB8721455D0 (en) | 1987-09-11 | 1987-10-21 | Lilly Industries Ltd | Capsules |
| HU205010B (en) * | 1987-09-15 | 1992-03-30 | Sandoz Ag | Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity |
| DE68900991D1 (de) * | 1988-01-29 | 1992-04-23 | Sankyo Co | Cyclosporin-zusammensetzungen. |
| US5376381A (en) * | 1988-02-25 | 1994-12-27 | The Liposome Company, Inc. | Integrity protected gelatin |
| US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| GB2222770B (en) * | 1988-09-16 | 1992-07-29 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporins |
| US4935293A (en) | 1988-10-25 | 1990-06-19 | Unifi, Inc. | Continuous multi-filament polyester substrate readily adherable to a vinyl sheet |
| US4935243A (en) * | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
| WO1991002520A1 (en) * | 1989-08-17 | 1991-03-07 | Cortecs Limited | Pharmaceutical formulations |
| US5532002A (en) * | 1989-08-17 | 1996-07-02 | Cortecs Limited | Gelatin pharmaceutical formulations |
| US5178877A (en) * | 1991-01-04 | 1993-01-12 | Abbott Laboratories | Encapsulated renin inhibitor composition |
| GB9113872D0 (en) * | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
| US6262022B1 (en) * | 1992-06-25 | 2001-07-17 | Novartis Ag | Pharmaceutical compositions containing cyclosporin as the active agent |
| RU2053764C1 (ru) * | 1991-07-19 | 1996-02-10 | Эгиш Дьедьсердьяр | Мягкая желатиновая капсула и способ ее получения |
| US5224294A (en) * | 1991-07-25 | 1993-07-06 | E. I. Du Pont De Nemours And Company | Hydroponic growth system |
| US5200191A (en) * | 1991-09-11 | 1993-04-06 | Banner Gelatin Products Corp. | Softgel manufacturing process |
| US5206219A (en) * | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
| DE4201178C2 (de) * | 1992-01-17 | 1995-12-07 | Alfatec Pharma Gmbh | Verfahren zur Herstellung von Weichgelatinekapseln nach einem Tropfverfahren |
| EP0573978B1 (en) * | 1992-06-12 | 1999-04-21 | Kao Corporation | Bath additive composition comprising surfactant-containing seamless capsules and method for producing the capsules. |
| US5626872A (en) * | 1992-06-16 | 1997-05-06 | Roemmers S.A.I.C.F. | Pharmaceutical soft capsules containing lysine clonixinate and a process for their preparation |
| SK278290B6 (en) | 1992-09-07 | 1996-08-07 | Milan Stuchlik | Medicaments with n-methylated cyclic undecapeptides |
| US5376293A (en) * | 1992-09-14 | 1994-12-27 | State Of South Dakota As Represented By The Department Of Transportation | Deicer |
| GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| JPH06157916A (ja) | 1992-11-30 | 1994-06-07 | Warner Lambert Kk | カプセル硬皮膜組成物 |
| US5376688A (en) * | 1992-12-18 | 1994-12-27 | R. P. Scherer Corporation | Enhanced solubility pharmaceutical solutions |
| US5431916A (en) * | 1993-04-29 | 1995-07-11 | The Procter & Gamble Company | Pharmaceutical compositions and process of manufacture thereof |
| CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| CN1077800C (zh) | 1993-07-01 | 2002-01-16 | 韩美药品工业株式会社 | 环孢菌素软胶囊组合物 |
| US5505961A (en) * | 1993-08-05 | 1996-04-09 | R. P. Scherer Corporation | Gelatin capsules containing a highly concentrated acetaminophen solution |
| US6204243B1 (en) * | 1993-09-01 | 2001-03-20 | Novatis Ag | Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis |
| IL110752A (en) * | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| EP1033128B2 (en) * | 1993-09-28 | 2011-11-23 | R.P. Scherer GmbH | Soft gelatin capsule manufacture |
| KR0146671B1 (ko) * | 1994-02-25 | 1998-08-17 | 김충환 | 사이클로스포린-함유 분말 조성물 |
| US5641512A (en) * | 1995-03-29 | 1997-06-24 | The Procter & Gamble Company | Soft gelatin capsule compositions |
| US5614217A (en) * | 1995-06-07 | 1997-03-25 | R.P. Scherer Corporation | Capsule shell formulation to produce brittle capsules |
| NZ280689A (en) * | 1995-12-15 | 1997-08-22 | Bernard Charles Sherma Sherman | Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol |
| US5958876A (en) | 1996-06-19 | 1999-09-28 | Novartis Ag | Cyclosporin-containing pharmaceutical compositions |
| NZ333657A (en) * | 1996-07-30 | 2000-05-26 | Novartis Ag | A pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin |
| US5798333A (en) * | 1996-09-17 | 1998-08-25 | Sherman; Bernard C. | Water-soluble concentrates containing cyclosporins |
| FR2755368B1 (fr) * | 1996-11-04 | 1999-03-19 | Oreal | Composition rincable pour le soin de la peau |
-
1994
- 1994-09-24 EP EP00103110A patent/EP1033128B2/en not_active Expired - Lifetime
- 1994-09-24 ES ES94115081T patent/ES2152281T3/es not_active Expired - Lifetime
- 1994-09-24 PT PT00103110T patent/PT1033128E/pt unknown
- 1994-09-24 SI SI9430349T patent/SI0649651T1/xx unknown
- 1994-09-24 ES ES00103110T patent/ES2308955T5/es not_active Expired - Lifetime
- 1994-09-24 SI SI9430487T patent/SI1033128T2/sl unknown
- 1994-09-24 PT PT94115081T patent/PT649651E/pt unknown
- 1994-09-24 DE DE69435104T patent/DE69435104D1/de not_active Expired - Lifetime
- 1994-09-24 AT AT00103110T patent/ATE398448T1/de active
- 1994-09-24 AT AT94115081T patent/ATE198041T1/de active
- 1994-09-24 EP EP94115081A patent/EP0649651B1/en not_active Expired - Lifetime
- 1994-09-24 DE DE69426408T patent/DE69426408T2/de not_active Expired - Lifetime
- 1994-09-24 DK DK94115081T patent/DK0649651T3/da active
- 1994-09-24 DK DK00103110.3T patent/DK1033128T4/da active
- 1994-09-24 EP EP00103109A patent/EP1029538A3/en not_active Withdrawn
- 1994-09-26 CA CA002302963A patent/CA2302963C/en not_active Expired - Lifetime
- 1994-09-26 GB GB9419353A patent/GB2282586B/en not_active Expired - Lifetime
- 1994-09-26 SK SK1157-94A patent/SK284268B6/sk not_active IP Right Cessation
- 1994-09-26 AU AU74237/94A patent/AU690571B2/en not_active Expired
- 1994-09-26 PE PE1994251434A patent/PE31295A1/es not_active IP Right Cessation
- 1994-09-26 FI FI944452A patent/FI120718B/fi not_active IP Right Cessation
- 1994-09-26 NZ NZ264536A patent/NZ264536A/en not_active IP Right Cessation
- 1994-09-26 PL PL94305188A patent/PL178884B1/pl unknown
- 1994-09-26 RU RU94034106A patent/RU2140783C1/ru active
- 1994-09-26 CA CA002132933A patent/CA2132933C/en not_active Expired - Lifetime
- 1994-09-26 NO NO19943563A patent/NO312334B1/no not_active IP Right Cessation
- 1994-09-26 IT ITRM940613A patent/IT1274931B/it active IP Right Grant
- 1994-09-26 CA CA002332631A patent/CA2332631C/en not_active Expired - Lifetime
- 1994-09-26 SG SG1996005680A patent/SG46531A1/en unknown
- 1994-09-26 SK SK847-2002A patent/SK285204B6/sk not_active IP Right Cessation
- 1994-09-26 IL IL11106794A patent/IL111067A/xx not_active IP Right Cessation
- 1994-09-27 CN CNB2004100974804A patent/CN100473377C/zh not_active Expired - Lifetime
- 1994-09-27 FR FR9411531A patent/FR2710532B1/fr not_active Expired - Lifetime
- 1994-09-27 CN CNB941160211A patent/CN1182842C/zh not_active Expired - Lifetime
- 1994-09-27 CZ CZ19942360A patent/CZ290314B6/cs not_active IP Right Cessation
- 1994-09-27 HU HU9402772A patent/HU221681B1/hu unknown
- 1994-09-27 JP JP6231107A patent/JP3071642B2/ja not_active Expired - Lifetime
- 1994-09-27 HU HU0105382A patent/HU228201B1/hu unknown
- 1994-09-28 ZA ZA947567A patent/ZA947567B/xx unknown
- 1994-09-28 KR KR1019940024487A patent/KR100200174B1/ko not_active Expired - Lifetime
- 1994-10-15 TW TW083109567A patent/TW438609B/zh not_active IP Right Cessation
-
1997
- 1997-04-29 US US08/841,734 patent/US5985321A/en not_active Expired - Lifetime
-
2000
- 2000-02-07 US US09/499,497 patent/US6589536B1/en not_active Expired - Fee Related
- 2000-10-17 US US09/690,401 patent/US6555132B1/en not_active Expired - Fee Related
- 2000-12-29 GR GR20000402869T patent/GR3035179T3/el unknown
-
2003
- 2003-05-13 US US10/437,098 patent/US7078054B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO312334B1 (no) | V¶skefylt mykgelatinkapsel og fremstilling derav | |
| US6039981A (en) | Antifungal oral composition containing itraconazole and process for preparing same | |
| US5589455A (en) | Cyclosporin-containing soft capsule compositions | |
| US6403122B1 (en) | Immunomodulatory pharmaceutical composition adopted to form lyotrophic liquid crystals in contact with an aqueous phase | |
| NO324852B1 (no) | Mykgelatinkapsler og deres fremstilling | |
| NO324355B1 (no) | Vaeskefylt mykgelatinkapsel | |
| US8940790B2 (en) | Stable pharmaceutical formulations comprising lubiprostone | |
| HK1078478B (en) | Process for manufacturing soft gelatin capsules | |
| HUP0001515A2 (hu) | Ciklosporin tartalmú gyógyszerkompozíciók |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |